May 16, 2016
New Data Analyses From Phase 3 ATTAIN Trials Support VIBATIV(R) (Telavancin) as a Treatment for Staphylococcus Aureus HABP/VABP, Including Cases Caused by MRSA
May 11, 2016
Theravance Biopharma to Present New Data Analyses From Phase 3 ATTAIN Trials of VIBATIV(R) (telavancin) in Treatment of HABP/VABP at American Thoracic Society 2016 International Conference
May 9, 2016
Theravance Biopharma, Inc. Reports First Quarter 2016 Financial Results and Provides Business Update
Medicines that make a difference®
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
In some instances, we partner our programs in order to accelerate timelines and better align resources.
Every day at Theravance Biopharma, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance Biopharma discovers, develops and brings important medicines to patients by: